Mitxelena A, Areses M. Bezlotoxumab can reduce the risk of Clostridium Difficile recurrence. Osag [Internet]. 2022 Jul. 29 [cited 2026 Nov. 11];6(1). Available from: https://aldizkariak.ueu.eus/index.php/osagaiz/article/view/362